(Q44145226)

English

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

scientific article published in August 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

revascularization

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

David J Moliterno

1

object named as

David J Moliterno

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Jean-Pierre Bassand

9

object named as

Jean-Pierre Bassand

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

5

object named as

Gregg W Stone

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Franz-Josef Neumann

7

object named as

Franz-Josef Neumann

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Howard C Herrmann

4

object named as

Howard C Herrmann

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Peter M DiBattiste

3

object named as

Peter M DiBattiste

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Steven J Yakubov

2

object named as

Steven J Yakubov

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

6

object named as

Carlos Macaya

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Diego Ardissino

8

object named as

Diego Ardissino

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Lynn Borzi

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Alan C Yeung

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Katherine A Harris

12

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Laura A Demopoulos

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

TARGET investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

360

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

9330

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

355-360

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909605-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(02)09605-8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44145226&oldid=2107107375"